SCHEDULE: Cormorant Asset Management Discloses 5.56% Stake in Rapport Therapeutics

Cormorant Asset Management, LP, through its associated funds, has reported beneficial ownership of 2,657,521 shares, representing 5.56% of the outstanding common stock of Rapport Therapeutics, Inc.

Summary

• Cormorant Asset Management, LP and Bihua Chen have filed a Schedule 13G, indicating their beneficial ownership of Rapport Therapeutics, Inc. common stock.
• The filing reports a total of 2,657,521 shares owned, which constitutes 5.56% of the company's outstanding common stock.
• This ownership level is based on the company's reported outstanding shares as of May 4, 2026.
• Cormorant Asset Management, LP acts as the investment adviser to the Cormorant Funds, which directly hold these shares.
• The filing is an amendment, indicating a change or update to previous ownership disclosures.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not controlling stake in Rapport Therapeutics, Inc. by Cormorant Asset Management, LP.

Positives

• Cormorant Asset Management, LP has taken a notable position in Rapport Therapeutics, Inc., signaling confidence in the company's prospects.
• The 5.56% stake represents a significant investment, potentially attracting further institutional interest.

Negatives

• The filing does not provide specific details on the acquisition cost or the exact timing of the share purchases, limiting a full financial assessment.
• The reporting persons explicitly state that the filing should not be construed as an admission of beneficial ownership for the purpose of Section 13 of the Act, which can create ambiguity.

Risks

• As a significant shareholder, Cormorant Asset Management, LP's future trading activity could impact Rapport Therapeutics' stock price.
• The filing does not detail any specific strategic intentions or potential influence over the issuer's control, leaving room for speculation.

Future Outlook

This filing is primarily a disclosure of current ownership and does not contain specific forward-looking statements or guidance from Rapport Therapeutics, Inc. itself. The future outlook for the company would be assessed through its own periodic filings.

Management Comments

• The filing should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings are common in the biotechnology and pharmaceutical sectors, often indicating active institutional interest in companies with promising drug pipelines or development stages. Rapport Therapeutics, Inc. operates in this dynamic sector.

Comparison to Industry Standards

• A 5.56% stake is a substantial holding for an institutional investor in the biotechnology sector, often placing them among the top shareholders.
• Competitors in the pharmaceutical and biotech space often see similar filings from investment firms like Cormorant Asset Management, LP, especially during periods of clinical trial progress or strategic shifts.
• The threshold for Schedule 13G filing (typically 5% ownership) signifies a level of investment that warrants public disclosure and can influence market perception.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor can be viewed positively, potentially signaling confidence and attracting further investment. However, future trading by Cormorant Asset Management could also introduce volatility.
• Management of Rapport Therapeutics, Inc.: The increased visibility from a substantial institutional holder may lead to greater scrutiny and engagement on corporate strategy and performance.
• Potential Investors: This filing provides information for potential investors to assess the company's shareholder base and the presence of significant institutional backing.

Next Steps

• Monitor future filings from Cormorant Asset Management, LP for any changes in their stake in Rapport Therapeutics, Inc.
• Observe Rapport Therapeutics, Inc.'s own SEC filings for strategic updates or financial performance that may influence investor sentiment.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the disclosure of a significant stake by Cormorant Asset Management, LP indicates institutional interest, it is a passive ownership filing (Schedule 13G) and does not provide new operational or financial performance data for Rapport Therapeutics, Inc. Further analysis of the company's underlying business, clinical trial progress, and financial health is required for a more definitive recommendation.

Keywords

Rapport Therapeutics, Cormorant Asset Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser, SEC Filing